- Home
- PETS vs CRVO Comparison
PETS vs CRVO Comparison
Compare PETS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- CRVO
- Stock Information
- Founded
- PETS 1996
- CRVO 2001
- Country
- PETS United States
- CRVO United States
- Employees
- PETS 287
- CRVO N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- CRVO Health Care
- Exchange
- PETS Nasdaq
- CRVO Nasdaq
- Market Cap
- PETS 68.6M
- CRVO 67.4M
- IPO Year
- PETS N/A
- CRVO N/A
- Fundamental
- Price
- PETS $3.39
- CRVO $5.87
- Analyst Decision
- PETS Sell
- CRVO Strong Buy
- Analyst Count
- PETS 2
- CRVO 8
- Target Price
- PETS $3.35
- CRVO $25.57
- AVG Volume (30 Days)
- PETS 142.9K
- CRVO 139.5K
- Earning Date
- PETS 08-05-2025
- CRVO 08-08-2025
- Dividend Yield
- PETS N/A
- CRVO N/A
- EPS Growth
- PETS N/A
- CRVO N/A
- EPS
- PETS 0.02
- CRVO N/A
- Revenue
- PETS $247,010,000.00
- CRVO $9,308,215.00
- Revenue This Year
- PETS N/A
- CRVO N/A
- Revenue Next Year
- PETS N/A
- CRVO N/A
- P/E Ratio
- PETS $192.80
- CRVO N/A
- Revenue Growth
- PETS N/A
- CRVO 15.14
- 52 Week Low
- PETS $2.90
- CRVO $1.80
- 52 Week High
- PETS $6.85
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- PETS 45.01
- CRVO 35.99
- Support Level
- PETS $3.13
- CRVO $5.45
- Resistance Level
- PETS $3.44
- CRVO $7.20
- Average True Range (ATR)
- PETS 0.18
- CRVO 0.51
- MACD
- PETS -0.00
- CRVO -0.08
- Stochastic Oscillator
- PETS 48.15
- CRVO 21.54
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.